{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:41:52Z","timestamp":1792572112120,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glaucoma remains a major cause of irreversible blindness and was estimated to affect 64.3\u00a0million people worldwide in 2013. Despite growing clinical use of minimally invasive glaucoma surgery (MIGS), reimbursement and uptake remain constrained by uncertainty about long-term cost-effectiveness. iStent-based trabecular micro-bypass implantation is commonly performed at the time of cataract surgery in patients with mild-to-moderate open-angle glaucoma, yet its economic value has not been synthesised systematically across healthcare systems.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the cost-effectiveness of iStent trabecular micro-bypass implantation performed concurrently with cataract surgery for mild-to-moderate open-angle glaucoma, and to examine how the analytic perspective and time horizon adopted in the underlying models relate to the decision the evidence is intended to inform.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review was performed of published model-based economic evaluations. Eligible studies used a formal decision-analytic model, reported quality-adjusted life years (QALYs), and evaluated an iStent device implanted concurrently with cataract surgery. PubMed, Embase, the Cochrane Library and Web of Science were searched on 27 July 2026 without date, language or publication-type restriction. Incremental cost-effectiveness ratios (ICERs), QALYs, analytic perspectives, time horizons, discount rates and probabilistic results were extracted with a page reference for each value. Reporting was appraised item-by-item against CHEERS 2022. Findings were synthesised narratively; no quantitative pooling was attempted. Reporting followed PRISMA 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 418 records identified and 293 after de-duplication, eight economic evaluations from eight countries met the eligibility criteria. All eight compared the device added to cataract surgery against cataract surgery alone; seven used a cohort Markov model and one an individual-patient microsimulation. Six adopted a payer or health-system perspective and two a societal perspective; five used a lifetime horizon, one 35 years and two 15 years. No evaluation adopted a provider perspective or a base-case horizon shorter than 15 years. All eight reported a favourable base-case result in the mild-to-moderate target population: reported ratios included \u20ac1,154 per QALY in France, \u20ac12,676 in Spain, \u20ac13,037 in Italy, \u20ac10,955 to \u20ac15,673 in Germany, JPY 1,430,647 in Japan and A$2,430 in Australia, together with two instances of dominance. Six of the eight were funded by the device manufacturer. Incremental QALY gains were small throughout, between approximately 0.005 and 0.17, so the reported ratios are highly sensitive to small changes in the denominator. One study did not report a price year and for a second it could not be verified; no study reported a pre-specified health economic analysis plan, and none modelled long-term structural change in medication prices, prescribing practice or competing alternatives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The included peer-reviewed models generally project that adding an iStent-family device to cataract surgery can be cost-effective over long horizons. That projection depends on sustained medication reduction, on extrapolated glaucoma progression and on local device and treatment costs. Direct evidence that the modelled long-term clinical benefit is realised in practice and offsets the acquisition cost remains limited: the evidence base is small, concentrated in industry-funded analyses of a single device family drawing largely on the same two-year pivotal trial, and built on incremental QALY gains close to zero. All included evaluations adopt a payer, health-system or societal perspective over 15 years or longer, and none addresses whether the marginal cost of adding a stent to an already-scheduled cataract procedure is justified within an annual operating budget. This is a gap in the included QALY-based cost-utility literature; the review was not designed to identify provider-perspective budget-impact analyses outside these eligibility criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Not applicable. This study is a systematic review of published economicevaluations; no clinical trial registration was required. The review was not registeredprospectively in PROSPERO.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12962-026-00846-6","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:13:37Z","timestamp":1792509217000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of iStent-based trabecular micro-bypass stenting combined with cataract surgery in mild-to-moderate open-angle glaucoma: a systematic review of analytic perspectives and time horizons"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4490-5263","authenticated-orcid":false,"given":"Dan","family":"Drobin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"issue":"11","key":"846_CR1","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","volume":"121","author":"YC Tham","year":"2014","unstructured":"Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081\u201390.","journal-title":"Ophthalmology"},{"issue":"3","key":"846_CR2","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/bjo.2005.081224","volume":"90","author":"HA Quigley","year":"2006","unstructured":"Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262\u20137.","journal-title":"Br J Ophthalmol"},{"issue":"18","key":"846_CR3","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2014.3192","volume":"311","author":"RN Weinreb","year":"2014","unstructured":"Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311(18):1901\u201311.","journal-title":"JAMA"},{"issue":"11","key":"846_CR4","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0886-3350(01)01036-7","volume":"27","author":"K Hayashi","year":"2001","unstructured":"Hayashi K, Hayashi H, Nakao F, Hayashi F. Effect of cataract surgery on intraocular pressure control in glaucoma patients. J Cataract Refractive Surg. 2001;27(11):1779\u201385.","journal-title":"J Cataract Refractive Surg"},{"issue":"9","key":"846_CR5","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1016\/j.ophtha.2012.02.050","volume":"119","author":"SL Mansberger","year":"2012","unstructured":"Mansberger SL, Gordon MO, Jampel H, Bhorade A, Brandt JD, Wilson B, Kass MA. Ocular Hypertension Treatment Study Group. Reduction in intraocular pressure after cataract extraction: the Ocular Hypertension Treatment Study. Ophthalmology. 2012;119(9):1826\u201331.","journal-title":"Ophthalmology"},{"issue":"6","key":"846_CR6","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.ophtha.2019.03.006","volume":"126","author":"TW Samuelson","year":"2019","unstructured":"Samuelson TW, Sarkisian SR Jr, Lubeck DM, Stiles MC, Duh YJ, et al. Prospective, randomized, controlled pivotal trial of an ab interno implanted trabecular micro-bypass in primary open-angle glaucoma and cataract: two-year results. Ophthalmology. 2019;126(6):811\u201321.","journal-title":"Ophthalmology"},{"issue":"2","key":"846_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ogla.2019.11.009","volume":"3","author":"IIK Ahmed","year":"2020","unstructured":"Ahmed IIK, Podbielski DW, Patel V, Falvey H, Murray J, Botteman M, Goeree R. A Canadian cost-utility analysis of 2 trabecular microbypass stents at time of cataract surgery in patients with mild to moderate open-angle glaucoma. Ophthalmol Glaucoma. 2020;3(2):103\u201313.","journal-title":"Ophthalmol Glaucoma"},{"key":"846_CR8","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"846_CR9","doi-asserted-by":"publisher","first-page":"e067975","DOI":"10.1136\/bmj-2021-067975","volume":"376","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMJ. 2022;376:e067975.","journal-title":"BMJ"},{"issue":"1","key":"846_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s41669-019-0141-4","volume":"4","author":"J Bartelt-Hofer","year":"2020","unstructured":"Bartelt-Hofer J, Ben-Debba L, Flessa S. Systematic review of economic evaluations in primary open-angle glaucoma: decision analytic modeling insights. PharmacoEconomics \u2013 Open. 2020;4(1):5\u201312.","journal-title":"PharmacoEconomics \u2013 Open"},{"key":"846_CR11","volume-title":"Making choices in health: WHO guide to cost-effectiveness analysis","year":"2003","unstructured":"Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, Murray CJL, editors. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003."},{"issue":"4","key":"846_CR12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1586\/14737167.2015.1103185","volume":"16","author":"CC Adarkwah","year":"2016","unstructured":"Adarkwah CC, van Gils PF, Hiligsmann M, Evers SMAA. Risk of bias in model-based economic evaluations: the ECOBIAS checklist. Expert Rev PharmacoEcon Outcomes Res. 2016;16(4):513\u201323.","journal-title":"Expert Rev PharmacoEcon Outcomes Res"},{"issue":"5","key":"846_CR13","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1177\/0272989X12458348","volume":"32","author":"AH Briggs","year":"2012","unstructured":"Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty: a report of the ISPOR\u2013SMDM Modeling Good Research Practices Task Force-6. Med Decis Making. 2012;32(5):722\u201332.","journal-title":"Med Decis Making"},{"issue":"6","key":"846_CR14","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/s10792-020-01314-7","volume":"40","author":"J Bartelt-Hofer","year":"2020","unstructured":"Bartelt-Hofer J, Flessa S. Comparative efficacy and cost-utility of combined cataract and minimally invasive glaucoma surgery in primary open-angle glaucoma. Int Ophthalmol. 2020;40(6):1469\u201379.","journal-title":"Int Ophthalmol"},{"issue":"1","key":"846_CR15","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1186\/s12913-021-06862-x","volume":"21","author":"AM Fea","year":"2021","unstructured":"Fea AM, Cattel F, Gandolfi S, Buseghin G, Furneri G, Costagliola C. Cost-utility analysis of trabecular micro-bypass stents (TBS) in patients with mild-to-moderate open-angle glaucoma in Italy. BMC Health Serv Res. 2021;21(1):824.","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"846_CR16","doi-asserted-by":"publisher","first-page":"e0252130","DOI":"10.1371\/journal.pone.0252130","volume":"16","author":"K Nieland","year":"2021","unstructured":"Nieland K, Labb\u00e9 A, Schweitzer C, Gicquel G, Kleintjens J, Ostawal A, Treur M, Falvey H. A cost-effectiveness analysis of iStent inject combined with phacoemulsification cataract surgery in patients with mild-to-moderate open-angle glaucoma in France. PLoS ONE. 2021;16(6):e0252130.","journal-title":"PLoS ONE"},{"issue":"4","key":"846_CR17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/17469899.2021.1939685","volume":"16","author":"MA Teus","year":"2021","unstructured":"Teus MA, Belda JI, Lav\u00edn C, Garc\u00eda-Feij\u00f3o J, Falvey H, Buseghin G, Soler M, Appierto M. Cost-effectiveness analysis of iStent inject\u00ae implantation during cataract surgery compared to cataract surgery alone for mild to moderate open-angle glaucoma patients in Spain. Expert Rev Ophthalmol. 2021;16(4):319\u201328.","journal-title":"Expert Rev Ophthalmol"},{"issue":"6","key":"846_CR18","doi-asserted-by":"publisher","first-page":"954","DOI":"10.18240\/ijo.2022.06.13","volume":"15","author":"A Igarashi","year":"2022","unstructured":"Igarashi A, Ishida K, Shoji N, Chu A, Falvey H, et al. iStent inject\u00ae and cataract surgery for mild-to-moderate primary open angle glaucoma in Japan: a cost-utility analysis. Int J Ophthalmol. 2022;15(6):954\u201361.","journal-title":"Int J Ophthalmol"},{"issue":"3","key":"846_CR19","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ogla.2021.09.006","volume":"5","author":"S Sood","year":"2022","unstructured":"Sood S, Heilenbach N, Sanchez V, Glied S, Chen S, Al-Aswad LA. Cost-effectiveness analysis of minimally invasive trabecular meshwork stents with phacoemulsification. Ophthalmol Glaucoma. 2022;5(3):284\u201396.","journal-title":"Ophthalmol Glaucoma"},{"issue":"3","key":"846_CR20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s41669-021-00312-4","volume":"6","author":"PR Healey","year":"2022","unstructured":"Healey PR, Tilden D, Jackson D, Aghajanian L. A cost-utility analysis of trabecular bypass devices versus usual care for patients with open-angle glaucoma. PharmacoEconomics \u2013 Open. 2022;6(3):355\u201365.","journal-title":"PharmacoEconomics \u2013 Open"},{"key":"846_CR21","volume-title":"The Green Book: UK government guidance on appraisal","author":"HM Treasury","year":"2026","unstructured":"HM Treasury. The Green Book: UK government guidance on appraisal. London: HM Treasury; 2026."}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-026-00846-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-026-00846-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-026-00846-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:03:39Z","timestamp":1792569819000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-026-00846-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["846"],"URL":"https:\/\/doi.org\/10.1186\/s12962-026-00846-6","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"30 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not required. This study is a systematic review based exclusively on published data and does not involve human participants, their data, or biological material.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Claude (Anthropic) was used, with author supervision, for search-strategy translation, record parsing and de-duplication, structured data extraction and manuscript drafting, as set out in Sect.\u00a0\n                      \n                      . All eligibility decisions, all verification of platform translations and extracted values against source documents, and final approval of the manuscript were performed by the author. No AI tool is credited as an author.","order":2,"name":"Ethics","label":"Use of AI Tools","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"128"}}